{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["10(2)"],"submitter":["Akkoc N"],"funding":["UCB Pharma"],"pubmed_abstract":["<h4>Introduction</h4>Biologic disease-modifying anti-rheumatic drugs (bDMARDs), including certolizumab pegol (CZP), are effective treatment options for the management of non-radiographic spondyloarthritis (nr-axSpA). In the absence of head-to-head comparisons in nr-axSpA, we conducted a systematic literature review (SLR) and indirect treatment comparison (ITC) to better understand the comparative efficacy of CZP vs. other bDMARDs.<h4>Methods</h4>Literature searches were conducted in October 2020 in MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials to identify randomized controlled trials in patients with nr-axSpA who had failed at least one non-steroidal anti-inflammatory drug and were treated with bDMARDs. Outcomes of interest included the Assessment of Spondyloarthr"],"journal":["Rheumatology and therapy"],"pagination":["307-327"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10011375"],"repository":["biostudies-literature"],"pubmed_title":["Comparative Efficacy of Biologic Disease-Modifying Anti-Rheumatic Drugs for Non-Radiographic Axial Spondyloarthritis: A Systematic Literature Review and Bucher Indirect Comparisons."],"pmcid":["PMC10011375"],"pubmed_authors":["Akkoc N","Betts M","Kiri S","Arteaga CH","Fahrbach K","Gaffney K","Mease PJ","Auteri SE","Neupane B","Kim M"],"additional_accession":[]},"is_claimable":false,"name":"Comparative Efficacy of Biologic Disease-Modifying Anti-Rheumatic Drugs for Non-Radiographic Axial Spondyloarthritis: A Systematic Literature Review and Bucher Indirect Comparisons.","description":"<h4>Introduction</h4>Biologic disease-modifying anti-rheumatic drugs (bDMARDs), including certolizumab pegol (CZP), are effective treatment options for the management of non-radiographic spondyloarthritis (nr-axSpA). In the absence of head-to-head comparisons in nr-axSpA, we conducted a systematic literature review (SLR) and indirect treatment comparison (ITC) to better understand the comparative efficacy of CZP vs. other bDMARDs.<h4>Methods</h4>Literature searches were conducted in October 2020 in MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials to identify randomized controlled trials in patients with nr-axSpA who had failed at least one non-steroidal anti-inflammatory drug and were treated with bDMARDs. Outcomes of interest included the Assessment of Spondyloarthr","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Apr","modification":"2025-04-05T13:32:25.493Z","creation":"2025-04-05T13:32:25.493Z"},"accession":"S-EPMC10011375","cross_references":{"pubmed":["36633815"],"doi":["10.1007/s40744-022-00522-0"]}}